Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

TCRT

Alaunos Therapeutics Inc

Jun 25 • 04:00PM ET

0.6746

Dollar change +0.0014
Percentage change 0.21	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.67	Insider Own	14.04%	Shs Outstand	16.01M	Perf Week	-29.73%
Market Cap	10.80M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	13.76M	Perf Month	-37.54%
Income	-26.77M	PEG	-	EPS next Q	-	Inst Own	14.67%	Short Float	10.33%	Perf Quarter	-64.68%
Sales	0.01M	P/S	1080.03	EPS this Y	-	Inst Trans	22.60%	Short Ratio	31.23	Perf Half Y	-7.27%
Book/sh	0.30	P/B	2.25	EPS next Y	-	ROA	-97.94%	Short Interest	1.42M	Perf Year	-90.03%
Cash/sh	0.26	P/C	2.61	EPS next 5Y	-	ROE	-156.09%	52W Range	0.61 - 7.80	Perf YTD	-36.39%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.41%	ROI	-558.14%	52W High	-91.35%	Beta	-0.49
Dividend TTM	-	Quick Ratio	4.87	Sales past 5Y	86.87%	Gross Margin	-47233.33%	52W Low	10.59%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	4.87	EPS Y/Y TTM	34.48%	Oper. Margin	-342716.67%	RSI (14)	28.62	Volatility	22.26% 11.51%
Employees	1	Debt/Eq	0.00	Sales Y/Y TTM	-99.79%	Profit Margin	-446233.33%	Recom	3.00	Target Price	112.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	83.30%	Payout	-	Rel Volume	0.90	Prev Close	0.67
Sales Surprise	-	EPS Surprise	-14.29%	Sales Q/Q	-	Earnings	-	Avg Volume	45.52K	Price	0.67
SMA20	-30.76%	SMA50	-40.65%	SMA200	-55.53%	Trades		Volume	41,073	Change	0.21%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-04-22	Resumed	Wells Fargo	Overweight	$3

May-15-24 10:55PM	TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024 (InvestorPlace) -7.39%
Apr-08-24 12:52PM	TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
Dec-18-23 07:57AM	Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? (InvestorPlace) +26.15%
Nov-14-23 07:56AM	Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today? (InvestorPlace) -10.59%
07:30AM	Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives (GlobeNewswire)
04:05PM	Loading…
Aug-14-23 04:05PM	Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives (GlobeNewswire) -64.68%
Jun-29-23 07:00AM	Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies (GlobeNewswire) +14.30%
May-25-23 05:00PM	Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -16.65%
May-10-23 07:00AM	Alaunos Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-03-23 08:30AM	Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-26-23 12:30PM	Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire) +6.57%
Mar-30-23 07:00AM	Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors (GlobeNewswire)
Mar-29-23 05:30PM	Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April (GlobeNewswire) +6.72%
Mar-07-23 07:00AM	Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-28-23 04:01PM	Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023 (GlobeNewswire)
05:47AM	Loading…
Feb-17-23 05:47AM	Alaunos Therapeutics, Inc.'s (NASDAQ:TCRT) largest shareholders are individual investors with 58% ownership, institutions own 22% (Simply Wall St.)
Jan-09-23 08:30AM	Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023 (GlobeNewswire)
Nov-29-22 09:01AM	Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -22.78%
Nov-28-22 04:01PM	Alaunos Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -5.84%
Nov-14-22 07:00AM	Alaunos Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -6.48%
Nov-08-22 08:30AM	Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022 (GlobeNewswire)
Nov-07-22 08:00AM	Alaunos Therapeutics to Present Data Highlighting its hunTR TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting (GlobeNewswire)
Sep-21-22 08:30AM	Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (GlobeNewswire) -20.87%
Sep-07-22 08:30AM	Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire) +18.21%
Sep-06-22 08:00AM	Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy (GlobeNewswire)
Aug-24-22 03:00PM	Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (GlobeNewswire) +20.00%
Aug-15-22 07:00AM	Alaunos Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire) +18.18%
Aug-08-22 08:50AM	Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022 (GlobeNewswire)
Aug-04-22 05:00PM	Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations (GlobeNewswire) +8.39%
Jul-06-22 09:31AM	Thinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics? (PR Newswire) +13.45%
07:07AM	Loading…
Jun-30-22 07:07AM	Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt In A Risky Way? (Simply Wall St.)
Jun-27-22 08:00AM	Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025 (GlobeNewswire) +17.27%
Jun-01-22 08:30AM	Alaunos Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) -8.63%
May-26-22 05:01PM	Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +11.09%
May-16-22 07:30AM	Alaunos Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) -15.15%
May-12-22 11:48AM	Insiders who placed huge bets on Alaunos Therapeutics, Inc. (NASDAQ:TCRT) earlier this year would be disappointed with the 27% drop (Simply Wall St.) +5.89%
May-10-22 08:30AM	Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +6.16%
May-09-22 08:30AM	Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022 (GlobeNewswire)
May-02-22 04:31PM	Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting (GlobeNewswire) -7.28% +12.66%
08:30AM	Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors (GlobeNewswire)
Mar-30-22 07:30AM	Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-22-22 01:58PM	What Percentage Of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Shares Do Insiders Own? (Simply Wall St.)
Mar-16-22 08:30AM	Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022 (GlobeNewswire) +8.41%
Mar-08-22 04:05PM	Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire) +21.63%

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boyle Kevin S. Sr.	Chief Executive Officer	Sep 01 '23	Sale	0.14	68,014	9,542	798,236	Sep 05 05:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TCRT

Alaunos Therapeutics Inc

Upgrade your FINVIZ experience